Troutman Pepper client MVM Partners, a health care investment firm focused on commercial stage companies, recently invested in Gynesonics® Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids. MVM Partners joins Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital in the investment. Read a press release about the financing.
A pioneer in women’s health, Gynesonics focuses on developing and delivering minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Its flagship product, the Sonata System®, is the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, a medical condition affecting roughly 80% of adult women.
The Troutman Pepper team advising MVM Partners in the financing included Dan Sieck, Chris Miller, and Alicia Worthy.
Consistently recognized as a top-tier national practice, Troutman Pepper’s corporate attorneys regularly handle transactions ranging in size from tens of millions of dollars to multibillion dollars. Core areas of service include private equity, venture capital, mergers and acquisitions (including cross-border transactions and corporate carve-outs), capital markets and corporate finance, corporate governance, and securities laws compliance. The firm also has particular expertise in advising clients on matters involving fund formation and fund management.
Original source can be found here.